Q-omics provides the consensus-scored ZEB1 profile across patient tissues and cancer cell-line models. ZEB1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZEB1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, ZEB1 RNA expression shows 26,170 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, KIRC, and BRCA as cancer lineages where ZEB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZEB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZEB1 survival associations across molecular data types. ZEB1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZEB1 RNA expression–survival associations across cancer types. High ZEB1 expression shows unfavorable associations in UVM, KIRP and MESO, but favorable associations in KIRC, SKCM and HNSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZEB1 RNA expression.
This table summarizes ZEB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZEB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZEB1 shows lower tumor expression in THCA, BLCA, LUSC and LUAD and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher ZEB1 RNA expression in tumor versus normal tissue (log2 FC = +0.886, t-test p < 0.001).
This table shows molecular features associated with ZEB1 in patient tissues and cancer cell lines. In patient samples, ZEB1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ZEB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
